COVALON TECHNOLOGIES LTD (COV.CA) Stock Fundamental Analysis
TSX-V:COV • CA22282D3022
1.9 CAD
0 (0%)
Last: Feb 27, 2026, 07:00 PM
COV gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 24 industry peers in the Biotechnology industry. COV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. COV scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make COV suitable for value investing!
1. Profitability
1.1 Basic Checks
- COV had positive earnings in the past year.
- COV had a positive operating cash flow in the past year.
- In multiple years COV reported negative net income over the last 5 years.
- In multiple years COV reported negative operating cash flow during the last 5 years.
1.2 Ratios
- COV has a better Return On Assets (5.70%) than 95.83% of its industry peers.
- The Return On Equity of COV (6.70%) is better than 95.83% of its industry peers.
- COV has a better Return On Invested Capital (3.92%) than 95.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 6.7% | ||
| ROIC | 3.92% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- COV has a better Profit Margin (6.27%) than 95.83% of its industry peers.
- With an excellent Operating Margin value of 5.37%, COV belongs to the best of the industry, outperforming 95.83% of the companies in the same industry.
- Looking at the Gross Margin, with a value of 53.24%, COV belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
- In the last couple of years the Gross Margin of COV has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.37% | ||
| PM (TTM) | 6.27% | ||
| GM | 53.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.84%
GM growth 5Y9.13%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so COV is destroying value.
- COV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 6.52 indicates that COV is not in any danger for bankruptcy at the moment.
- COV has a better Altman-Z score (6.52) than 87.50% of its industry peers.
- The Debt to FCF ratio of COV is 1.56, which is an excellent value as it means it would take COV, only 1.56 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of COV (1.56) is better than 91.67% of its industry peers.
- A Debt/Equity ratio of 0.05 indicates that COV is not too dependend on debt financing.
- With a decent Debt to Equity ratio value of 0.05, COV is doing good in the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 1.56 | ||
| Altman-Z | 6.52 |
ROIC/WACC0.49
WACC8%
2.3 Liquidity
- COV has a Current Ratio of 8.36. This indicates that COV is financially healthy and has no problem in meeting its short term obligations.
- COV has a Current ratio of 8.36. This is amongst the best in the industry. COV outperforms 87.50% of its industry peers.
- A Quick Ratio of 6.40 indicates that COV has no problem at all paying its short term obligations.
- The Quick ratio of COV (6.40) is better than 91.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
- The earnings per share for COV have decreased strongly by -82.26% in the last year.
- Looking at the last year, COV shows a small growth in Revenue. The Revenue has grown by 5.29% in the last year.
- The Revenue has been growing by 19.43% on average over the past years. This is quite good.
EPS 1Y (TTM)-82.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)5.29%
Revenue growth 3Y21.83%
Revenue growth 5Y19.43%
Sales Q2Q%-17.09%
3.2 Future
- The Earnings Per Share is expected to grow by 27.23% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 6.47% on average over the next years.
EPS Next Y76.57%
EPS Next 2Y43.53%
EPS Next 3Y35.75%
EPS Next 5Y27.23%
Revenue Next Year6.67%
Revenue Next 2Y6.81%
Revenue Next 3Y6.78%
Revenue Next 5Y6.47%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 63.33, the valuation of COV can be described as expensive.
- Based on the Price/Earnings ratio, COV is valued cheaply inside the industry as 95.83% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.07. COV is valued rather expensively when compared to this.
- The Price/Forward Earnings ratio is 13.18, which indicates a correct valuation of COV.
- COV's Price/Forward Earnings ratio is rather cheap when compared to the industry. COV is cheaper than 91.67% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.05. COV is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.33 | ||
| Fwd PE | 13.18 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, COV is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, COV is valued cheaper than 91.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.39 | ||
| EV/EBITDA | 13.74 |
4.3 Compensation for Growth
- COV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of COV may justify a higher PE ratio.
- A more expensive valuation may be justified as COV's earnings are expected to grow with 35.75% in the coming years.
PEG (NY)0.83
PEG (5Y)N/A
EPS Next 2Y43.53%
EPS Next 3Y35.75%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 7.89%, COV is a good candidate for dividend investing.
- COV's Dividend Yield is rather good when compared to the industry average which is at 0.42. COV pays more dividend than 100.00% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.82, COV pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.89% |
5.2 History
- COV is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y43.53%
EPS Next 3Y35.75%
TSX-V:COV (2/27/2026, 7:00:00 PM)
1.9
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2026-02-25/bmo
Earnings (Next)05-26 2026-05-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.08%
Ins Owner ChangeN/A
Market Cap52.48M
Revenue(TTM)32.82M
Net Income(TTM)2.06M
Analysts84.44
Price Target2.96 (55.79%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.89% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.14%
Min EPS beat(2)-100%
Max EPS beat(2)124.27%
EPS beat(4)3
Avg EPS beat(4)86.97%
Min EPS beat(4)-100%
Max EPS beat(4)229.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.25%
Min Revenue beat(2)-19.53%
Max Revenue beat(2)-12.98%
Revenue beat(4)1
Avg Revenue beat(4)-1.09%
Min Revenue beat(4)-19.53%
Max Revenue beat(4)32.12%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.33 | ||
| Fwd PE | 13.18 | ||
| P/S | 1.6 | ||
| P/FCF | 36.39 | ||
| P/OCF | 22.92 | ||
| P/B | 1.71 | ||
| P/tB | 1.79 | ||
| EV/EBITDA | 13.74 |
EPS(TTM)0.03
EY1.58%
EPS(NY)0.14
Fwd EY7.59%
FCF(TTM)0.05
FCFY2.75%
OCF(TTM)0.08
OCFY4.36%
SpS1.19
BVpS1.11
TBVpS1.06
PEG (NY)0.83
PEG (5Y)N/A
Graham Number0.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 6.7% | ||
| ROCE | 5.45% | ||
| ROIC | 3.92% | ||
| ROICexc | 8.47% | ||
| ROICexgc | 9.31% | ||
| OM | 5.37% | ||
| PM (TTM) | 6.27% | ||
| GM | 53.24% | ||
| FCFM | 4.39% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.84%
GM growth 5Y9.13%
F-Score4
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 1.56 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 88.69% | ||
| Cap/Sales | 2.58% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 84.21% | ||
| Profit Quality | 70.07% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 6.52 |
F-Score4
WACC8%
ROIC/WACC0.49
Cap/Depr(3y)88.92%
Cap/Depr(5y)79.37%
Cap/Sales(3y)2.96%
Cap/Sales(5y)3.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y76.57%
EPS Next 2Y43.53%
EPS Next 3Y35.75%
EPS Next 5Y27.23%
Revenue 1Y (TTM)5.29%
Revenue growth 3Y21.83%
Revenue growth 5Y19.43%
Sales Q2Q%-17.09%
Revenue Next Year6.67%
Revenue Next 2Y6.81%
Revenue Next 3Y6.78%
Revenue Next 5Y6.47%
EBIT growth 1Y-18.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year924.16%
EBIT Next 3Y139.18%
EBIT Next 5Y77.12%
FCF growth 1Y-52.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.09%
OCF growth 3YN/A
OCF growth 5YN/A
COVALON TECHNOLOGIES LTD / COV.CA FAQ
Can you provide the ChartMill fundamental rating for COVALON TECHNOLOGIES LTD?
ChartMill assigns a fundamental rating of 6 / 10 to COV.CA.
What is the valuation status for COV stock?
ChartMill assigns a valuation rating of 7 / 10 to COVALON TECHNOLOGIES LTD (COV.CA). This can be considered as Undervalued.
Can you provide the profitability details for COVALON TECHNOLOGIES LTD?
COVALON TECHNOLOGIES LTD (COV.CA) has a profitability rating of 6 / 10.
What is the financial health of COVALON TECHNOLOGIES LTD (COV.CA) stock?
The financial health rating of COVALON TECHNOLOGIES LTD (COV.CA) is 8 / 10.